Advancements in Drug Development and Formulation

whitePaper | November 3, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result of a collaborative process facilitated and endorsed by the World Economic.

whitePaper | February 20, 2023

Once the industry has normalized after a turbulent 2020, life sciences leaders can still count on continued change. The future will be challenging at best without the support of next-gen BI as life sciences navigate their businesses through new or growing competition, economic recovery, regulatory and political pressures, barriers to market access, and an increased demand for personalized medicine.

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

whitePaper | December 13, 2022

Viral vectors are a critical part of the advanced therapies supply chain as they are used to introduce the gene of interest, whether that’s into a cell intended for therapeutic gene transfer or for direct viral-mediated gene transfer into the patient.

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.